Phase I Glioblastoma Cancer Vaccine Trial Shows Promise for Patients and Novel Vaccine Platform
Phase I Glioblastoma Cancer Vaccine Trial Shows Promise for Patients and Novel Vaccine Platform https://pediatricsnationwide.org/wp-content/uploads/2026/05/AdobeStock_130277597-1024x683.jpeg 1024 683 Katie Brind'Amour, PhD, MS, CHES https://pediatricsnationwide.org/wp-content/uploads/2021/03/Katie-B-portrait.gif
Early results suggest extended survival and the potential to manufacture customized vaccines that target up to 40 patient-specific neoantigens. Glioblastoma is the most common primary central nervous system cancer in adults. Highly heterogenous from patient to patient and even within a single tumor, it is notoriously hard to treat — especially for a subgroup of…